BiotechTube

SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811

Phase 3Active
0 watching 0 views this weekπŸ“ˆ Rising
77
Hype Score

Development Stage

βœ“
Pre-clinical
βœ“
Phase 1
βœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Conditions

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Trial Timeline

Aug 4, 2022 β†’ Dec 31, 2027

NCT ID
NCT05424835

About SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811

SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811 is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane. The current trial status is active. This product is registered under clinical trial identifier NCT05424835. Target conditions include HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05424835Phase 3Active

Competing Products

20 competing products in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

See all competitors
ProductCompanyStageHype Score
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
CT-0508 + PembrolizumabCarisma TherapeuticsPhase 1
25
CT-0525Carisma TherapeuticsPhase 1
25
TrastuzumabCelltrionPhase 3
77
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
YH32367YuhanPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
77
DS-8201a + T-DM1Daiichi SankyoPhase 3
77
Pertuzumab + Trastuzumab + eribulinEisaiPhase 2
52
Tucatinib 150 MG + Trastuzumab + CapecitabineBioconPhase 2
52
SHR-A1811 Injection + SHR-A1811 Injection οΌ› Pertuzumab Injection + Trastuzumab InjectionοΌ›Pertuzumab Injection οΌ› Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
77
PyrotinibJiangsu Hengrui MedicinePre-clinical
23
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
77
Pyrotinib + Placebo Oral Tablet + Trastuzumab + DocetaxelJiangsu Hengrui MedicinePhase 3
77
SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ IrinotecanJiangsu Hengrui MedicinePhase 3
77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85